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Small colony variants (SCVs) of the human pathogen Staphylococcus aureus are
associated with persistent infections. Phenotypically, SCVs are characterized by slow
growth and they can arise upon interruption of the electron transport chain that
consequently reduce membrane potential and thereby limit uptake of aminoglycosides
(e.g., gentamicin). In this study, we have examined the pathways by which the fitness
cost of SCVs can be ameliorated. Five gentamicin resistant SCVs derived from S. aureus
JE2 were independently selected on agar plates supplemented with gentamicin. The
SCVs carried mutations in the menaquinone and hemin biosynthesis pathways, which
caused a significant reduction in exponential growth rates relative to wild type (WT;
0.59–0.72) and reduced membrane potentials. Fifty independent lineages of the low-
fitness, resistant mutants were serially passaged for up to 500 generations with or
without sub-lethal concentrations of gentamicin. Amelioration of the fitness cost followed
three evolutionary trajectories and was dependent on the initial mutation type (point
mutation vs. deletion) and the passage condition (absence or presence of gentamicin).
For SCVs evolved in the absence of gentamicin, 12 out of 15 lineages derived from
SCVs with point mutations acquired intra-codonic suppressor mutations restoring
membrane potential, growth rate, gentamicin susceptibility and colony size to WT
levels. For the SCVs carrying deletions, all lineages enhanced fitness independent of
membrane potential restoration without alterations in gentamicin resistance levels. By
whole genome sequencing, we identified compensatory mutations in genes related
to the Bσ stress response (7 out of 10 lineages). Inactivation of rpoF that encode
for the alternative sigma factor SigB ( Bσ ) partially restored fitness of SCVs. For all
lineages passaged in the presence of gentamicin, fitness compensation via membrane
potential restoration was suppressed, however, selected for secondary mutations in
fusA and SAUSA300_0749. This study is the first to describe fitness compensatory
events in SCVs with deletion mutations and adaptation of SCVs to continued exposure
to gentamicin.
Keywords: Staphylococcus aureus, evolution, gentamicin, resistance, small colony variants, electron transport
chain
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INTRODUCTION
The long-term stability of antibiotic resistance in a bacterial
population is dependent on several key parameters, namely the
fitness cost of the resistance mechanism, the selection pressure
for maintaining it conferred by the level of antibiotic usage in
hospital and community settings and the rate of compensatory
evolution ameliorating its potential biological cost (Barbosa
and Levy, 2000; Andersson, 2006; Andersson and Hughes,
2010, 2011). In the majority of investigated cases, chromosomal
and plasmid encoded antibiotic resistance mechanisms carry a
fitness cost in terms of reduced competitiveness to sensitive
isolates and are therefore selected against in the absence of
antimicrobial selection pressure (Andersson, 2006; Andersson
and Hughes, 2010; Vogwill and MacLean, 2015). The adverse
effect of the resistance mechanism can, however, be suppressed
via compensatory events, increasing fitness of the resistant
organism and thereby stabilizing the resistance mechanism
in the bacterial population in the absence of antimicrobial
selection pressure (Andersson and Hughes, 2010). Compensatory
genetic events have been extensively studied in the suppression
of the adverse effects of target-site resistance mutations
(Björkman et al., 1998; Reynolds, 2000; Paulander et al.,
2007; Paulander et al., 2010; Brandis et al., 2012). In these
cases, selection has mainly been for compensatory events
restoring the enzymatic activity that was reduced by the
resistance mutation (Björkman et al., 1998; Reynolds, 2000;
Paulander et al., 2007, 2010; Brandis et al., 2012). Examples
include rifampicin resistance mutations in rpoB (Reynolds, 2000;
Brandis et al., 2012), streptomycin resistance mutations in rpsL
(encoding ribosomal S12 protein) (Björkman et al., 1998) and
mupirocin resistance mutations in the ileS (encoding isoleucyl-
tRNA synthetase) (Paulander et al., 2007, 2010). Contrarily,
compensation of the fitness cost conferred by non-target-site
resistance mechanisms is not well understood. One example
of a non-target-site resistance mechanism conferring a high
fitness cost is reduced aminoglycoside (e.g., gentamicin) uptake
in S. aureus.
Gentamicin uptake is dependent on the membrane potential,
which can be greatly reduced when the flow of electrons in
the electron transport chain is impaired (Taber et al., 1987).
This can occur through chemical inhibition of the electron
transport chain (Hoffman et al., 2006; McCollister et al., 2011)
or via mutations in the pathways for menaquinone and hemin
biosynthesis (Schaaff et al., 2003; von Eiff et al., 2006; Lannergård
et al., 2008, 2011; Mayfield et al., 2013; Dean et al., 2014). In
S. aureus, the electron acceptors hemin of the cytochromes and
menaquinone (isoprenylated form of menadione) are required
for electron flow in the electron transport chain (McNamara and
Proctor, 2000). The insufficient flow of electrons in the electron
transport chain that limits the establishment of the proton
gradient across the cell membrane not only confers reduced
uptake of aminoglycosides, but also causes large physiological
changes in the cell, e.g., shifting metabolism from respiration
to fermentation (McNamara and Proctor, 2000). Phenotypically
the reduction in membrane potential leads to the appearance
of small colonies on agar plates, hence the commonly accepted
name of these being small colony variants (SCVs). In the
Gram-positive opportunistic pathogen S. aureus, gentamicin
resistant SCVs display reduced hemolysis due to decreased alpha-
toxin production on blood agar plates, lack of pigmentation
and often auxotrophy to either menadione or hemin (Proctor
et al., 2006). The fitness cost of S. aureus SCVs with reduced
membrane potential is associated with decreased ATP production
(Proctor et al., 1998; Kohler et al., 2003), the inability to
utilize of a wide range of sugars, such as mannitol, xylose,
lactose, sucrose, maltose and glycerol (McNamara and Proctor,
2000) and the inability to re-utilize lactate that is produced
during growth on glucose (Baumert et al., 2002). However, the
SCV phenotype can be unstable in the absence of antibiotic
selection pressure, which may lead to the reversion to wild
type (WT) colony phenotype and the concomitant loss of
aminoglycoside resistance (Lannergård et al., 2008; Tuchscherr
et al., 2011).
The presences of SCVs in patients have been associated
with persistent infections that are difficult to treat with
antibiotic therapy, indicating a selection for this phenotype
during persistent infections and antibiotic therapy (Kahl
et al., 2016). Given the clinical success of SCVs and the
ability to cause recurrent infections, it is important to
examine compensatory adaptation to the fitness cost of SCVs
and determine if concurrent antibiotic treatment affects the
compensation. Previously a few studies have addressed this
question, showing that reversion to normal colony phenotype can
proceed via compensatory intragenic mutations in SCV isolates
carrying point mutations in environments with no selection
pressure (Lannergård et al., 2008; Pränting and Andersson,
2011).
The aim of the study was to use experimental evolution to
determine the fitness compensatory events that take place in
gentamicin resistant SCVs carrying either point mutations or
deletions and assess how the presence of gentamicin affects fitness
compensation.
MATERIALS AND METHODS
Strains, Media, Auxotrophy and MIC
Determination
All strains used in this study are derivatives of the S. aureus
JE2 (Table 1). The following transposon mutants were retrieved
from the Nebraska Transposon Mutant Library (Fey et al.,
2013): JE2 hemB::8N6 (NE1845), JE2 menD::8N6 (NE1345),
JE2 rpoF::8N6 (NE1109) and JE2 SAUSA300_1252::8N6
(NE142). Strains were grown in TSB at 37◦C with shaking at
200 rpm or on TSA agar plates with or without addition of
gentamicin (Sigma). Minimal inhibitory concentrations (MICs)
of gentamicin were determined using a twofold microbroth
dilution assay according to Wikler and Clinical and Laboratory
Standards Institute [CLSI] (2009) guidelines, except that
cation-adjusted Mueller Hinton broth was substituted with
TSB. Auxotrophy of selected gentamicin resistant SCVs was
determined by visual growth compensation on TSA plates
supplemented with menadione (1 µg/ml) (Sigma) or hemin
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TABLE 1 | Strains used in this study.
Strain Description Source
S. aureus JE2 CA-MRSA USA300, ErmS, plasmid
cured LAC derivative
Fey et al., 2013
NE1845 JE2 hemB::8N6, ErmR Fey et al., 2013
NE1345 JE2 menD::8N6, ErmR Fey et al., 2013
NE1109 JE2 rpoF::8N6, ErmR Fey et al., 2013
NE142 JE2 SAUSA300_1252::8N6, ErmR Fey et al., 2013
MV108 SCV selected on gentamicin (4 µg/ml) This study
MV112 SCV selected on gentamicin (4 µg/ml) This study
MV118 SCV selected on gentamicin (4 µg/ml) This study
MV123 SCV selected on gentamicin (4 µg/ml) This study
MV127 SCV selected on gentamicin (4 µg/ml) This study
MV216 MV118 rpoF::8N6, ErmR This study
MV218 MV118 SAUSA300_1252::8N6, ErmR This study
(1µg/ml) (Sigma). Construction of MV118 rpoF::8N6 (MV216)
and MV118 SAUSA300_1252::8N6 (MV218) mutants was
performed by transduction with bacteriophage ϕ11, selecting
for transductants on erythromycin plates (5 µg/ml) (Fey et al.,
2013).
Selection of Gentamicin Resistant SCVs
Selection of spontaneous gentamicin resistant SCVs was
performed on TSA plates supplemented with 4 µg/ml of
gentamicin, by applying proper dilutions of JE2 over-night
(ON) cultures on the plates. SCV colonies were picked after
48 h of incubation and re-streaked on gentamicin-free TSA
plates to examine the stability of the SCV phenotype. If no
revertants appeared in the re-streak, one colony from each
independent selection was saved. The mutation frequency of
gentamicin resistant SCVs was calculated as the ratio of the
number of gentamicin resistant mutants divided by the total
number of cells (determined by plating proper dilutions on TSA
plates).
PCR, Sanger-Sequencing and DNA
Isolation
Genomic DNA (gDNA) was isolated from 1 ml ON cell culture
using DNeasy Blood and Tissue Kit (Qiagen). Cell lysis prior
to gDNA isolation was achieved by pre-treating ON cultures
with lysostaphin (5 mg/ml) for 1–2 h. Genes were amplified
with two primer pairs to secure proper quality along the entire
genes of interest. Genes of interest were amplified by PCR using
Taq DNA polymerase (Thermo Scientific). Primers used for
amplification are available in Supplementary Table S1. The PCR
program used for amplification was: 5 min denaturation at 95◦C,
followed by 30 cycles of (i) denaturation 95◦C for 30 s, (ii)
annealing at proper temperature for 30 s for each primer pair
and (iii) elongation for 1 min/kb at 72◦C. A final elongation
step of 5 min was included. Amplification products were
verified by gel electrophoresis and DNA concentration measured
on a NanoDrop 1000 (Thermo Scientific). Sanger-sequencing
was performed by Macrogen Europe Inc (Amsterdam, the
Netherlands).
Genome Sequencing and Mutation
Analysis
Whole genome sequencing was performed at the Department
of Clinical Microbiology at Hvidovre Hospital on a MiSeq
(Illumina, San Diego, CA, USA). DNA concentrations were
normalized using a Qubit (Invitrogen, UK). Libraries were made
with Nextera XT DNA sample preparation kit (Illumina, US),
genomes multiplexed to 24 isolates per run and sequenced with
2 × 150 bp paired-end reads. Analysis of output reads from
the MiSeq was performed in CLC Genomics Workbench version
8.0. Reads were aligned to the S. aureus USA300_FPR3757
reference genome (Genbank accession no. NC_07793). Variants
were called at standard settings. To exclude false-positive variant
calls due to alignment of reads to the S. aureus USA300_FPR3757
reference genome, we sequenced the JE2 strain that is the
ancestral strain of the selected SCVs. Variants identified in
our JE2 sequence were excluded in the selected SCVs and
evolved strains by the function ‘Filter Variants against Control
Reads.’
Compensatory Evolution Experiment
Compensatory evolution was performed in TSB and in TSB
supplemented with gentamicin at 1/2 MIC of the respective
SCV strain. Five independent lineages started from single
colonies for each strain were passaged under both culturing
conditions. The evolution experiment was performed via serial
passaging in 10 ml falcon tubes containing 1 ml growth
medium in each tube for proper aeration. Every 24 h 1 µl,
corresponding to approximately 106 cells, was transferred into
fresh growth medium, allowing for growth of approximately 10
generations per transfer. After every 50 generations of evolution,
samples from each lineage were plated on TSA plates and
visually inspected for growth compensation based on colony
size. Restored fitness in compensated lineages could also be
recognized by visual inspection of the culture cell density. If
cells in a lineage reverted to normal colony phenotype, one
colony was saved from that lineage. The strains not showing
changes in colony size were passaged for 50 days (∼500
generations), at which point one colony from each lineage was
saved.
Fitness Measurements
Fitness was estimated by two parameters. (i) Growth rates in
exponential phase were measured in a Bioscreen C reader (Oy
Growth Curves Ab) at 37◦C. Bacteria from ON cultures were
diluted to a final concentration of 106 CFU/ml in 1 ml TSB
or in 1 ml TSB supplemented with gentamicin (1/2 MIC of the
parent SCV strain). Three hundred microliter was transferred
to each well of the bioscreen plate with measurements taken
every 5 min at 600 nm wavelength. The relative growth rates
were calculated as the growth rate of the mutant divided by the
growth rate of the WT strain. Three biological replicates were
performed for each mutant, with three technical replicates per
biological. (ii) colony forming unit (CFU) counts at stationary
phase after 24 h growth was determined by growing cells in
1 ml TSB in a 10 ml falcon tube with constant shaking at
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200 rpm. Cells from ON cultures were diluted to a starting
inoculum of 106 CFU/ml. CFU quantification was determined on
TSA plates. Three biological replicates were performed for each
strain.
Membrane Potential Measurements
Using Flow Cytometry
Assessment of variations in membrane potential was estimated
using a flow cytometry assay based on the BacLight Bacterial
Membrane Potential Kit (LifeTechnologies). Cells from ON
cultures were inoculated in 30 ml TSB in 300 ml Erlenmeyer
flasks and grown to an OD600 of 0.2. Fifteen microliter culture
was transferred to 1 ml filtered phosphate-buffered saline
(PBS). To each cell solution 10 µl of fluorescent membrane
potential indicator dye, DiOC2(3), was added and cells were
stained for 30 min at room temperature. Data was recorded
on a BD Biosciences Accuri C6 flow cytometer (Becton,
Dickinson and Company), with emission filters suitable for
detecting red and green fluorescence. Settings on the flow
cytometer were as follows: 50000 recorded events at a FSC
threshold of 15000 and medium flow rate. Gating of stained
cell population and analysis of flow cytometry data were
performed in CFlow R© (BD Accuri). As an indicator of membrane
potential the ratio of red to green fluorescence intensity was
calculated. The assay was verified using the two SCV strains
with transposon insertions in hemB (NE1845) and menD
(NE1345).
Statistics
Significant difference was calculated by 1-way ANOVA, with
a post-hoc analysis of Tukey’s Multiple Comparison Tests
(∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). Statistical analysis was
performed in GraphPad Prism 4 (GraphPad Software, Inc.).
Nucleotide Sequence Accession
Numbers
Sequence reads from all isolates are deposited in the European
Nucleotide Archive under study accession no. PRJEB15409.
RESULTS
Mutations Conferring Resistance to
Gentamicin
Spontaneous gentamicin resistant mutants were selected on
TSA plates containing 4 µg/ml gentamicin, corresponding to
2x MIC of WT S. aureus JE2. All resistant mutants displayed
a small colony phenotype and were selected with an average
frequency of 2 × 10−6. Five mutants showing a stable small
colony phenotype when restreaked on antibiotic-free plates
were whole genome sequenced (WGS) in order to identify the
resistance conferring mutations. Only a single mutation was
identified for each mutant (Table 2). Four mutations were
located in the menaquinone (MenA Asn198Lys and MenD
Ala413fs) and hemin (HemH Glu263* and HemB Pro240Leu)
biosynthesis pathways. The fifth strain contained a deletion in
the SAUSA300_1683 gene (SAUSA300_1683 Leu274fs), encoding
for the bi-functional enzyme 3-deoxy-7-phosphoheptulonate
synthase [EC: 2.5.1.54]/chorismate mutase [EC: 5.4.99.5]. This
enzyme is required for the biosynthesis of chorismate, the first
precursor molecule of the menaquinone biosynthesis pathway
(Wakeman et al., 2012). All five mutants displayed a significant
reduction in membrane potential, when assayed with the
indicator dye, DiOC2(3) (Table 2). The reduction in membrane
potential of the SCVs correlated with 8–16 times increased
gentamicin MIC (16–32 µg/ml), compared to the MIC of the
WT strain (2 µg/ml). The menD and SAUSA300_1683 displayed
menadione auxotrophy, while the hemH and hemB displayed
hemin auxotrophy. Growth complementation with menadione
could not be achieved for menA (Lannergård et al., 2011)
(Table 2).
Fitness of Resistant Mutants
We estimated the fitness cost of the SCV mutations using two
parameters (i) exponential growth rate and (ii) CFU in stationary
phase. The relative growth rate of the five SCV mutants were
0.59–0.72 in TSB, while being 0.49–0.62 in TSB supplemented
with gentamicin compared to the WT strain grown in TSB
(Table 2; Figure 1). Furthermore, the SCVs experienced 10–30
fold lower CFUs in stationary phase, when grown in TSB
(Figure 2).
Fitness Compensation of SCV Mutants
To investigate if fitness could be ameliorated in the SCVs
and address the compensatory mechanisms involved, we
conducted an evolution experiment with and without sub-
lethal concentrations of gentamicin (1/2 MIC), selecting for
mutants with improved fitness. For each SCV mutant we
passaged five lineages without and five lineages with gentamicin
and at regular intervals screened for higher fitness by visual
examination of bacterial colony size on TSA plates. To separate
potential adaptation to the growth medium from SCV specific
compensatory events we passaged five WT lineages for 500
generations in TSB in parallel. None of the evolved WT lineages
displayed improved fitness in terms of exponential growth rate or
stationary CFU count, indicating that S. aureus JE2 is generally
well adapted to growth in TSB (Figures 1 and 2).
Out of the 50 passaged lineages, only 12 reverted to WT
colony size (Supplementary Table S2). All of the 12 lineages
originated from SCVs containing point mutations (hemH, menA
or hemB) and the reversion occurred only when passaged without
gentamicin. Interestingly, in a single passage (∼10 generations)
revertants with WT colony size accounted approximately for
50% of the total colonies in the population (tested upon
plating on antibiotic-free plates), where no revertants had been
observed at the former passage. This fast take over cannot
be explain solely with increased growth rates but might also
indicate that revertants utilize nutrients that the SCV mutant
cannot, which is supported by the observation that revertants
grow to approximately 10-fold higher cell densities than SCVs
(Figure 2). Reversion to WT colony size proceeded within 50–310
generations for the 12 lineages. As the reverted clones in a single
passage constituted 50% of the population, the rate for reversion
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TABLE 2 | Genotypic and phenotypic characterization of selected SCVs.
Strain Genotype MIC (µg/ml) RGR Auxotrophy MP
Gene Nucleotide AA
JE2 WT – – 2 1 – 1
MV108 hemH G787T Glu263∗ 32 0.64 Hemin 0.09
MV112 SAUSA300_1683 820_823delTTAG Leu274fs 32 0.59 Menadione 0.07
MV118 menD 1237_1238delGC Ala413fs 32 0.63 Menadione 0.09
MV123 hemB C746T Pro249Leu 16 0.60 Hemin 0.14
MV127 menA T594A Asn198Lys 32 0.72 – 0.07
Identification of SCV conferring mutations on nucleotide and amino acid (AA) level, and phenotypic traits, such as gentamicin MIC, relative growth rate in TSB (RGR) to WT,
auxotrophy to menadione and hemin, and relative impact on membrane potential (MP) assayed with DiOC2(3). The fluorescent dye DiOC2(3) exhibits green fluorescence
in bacterial cells and shifts toward red fluorescence, when the dye molecules self-associate at higher cytosolic concentrations caused by larger membrane potentials. The
red/green ratio of wild type WT is set to 1.
FIGURE 1 | Relative growth rates of SCV mutants and evolved lineages. The growth rate of wild type (square) is set to 1. Relative growth rates of five
ancestral SCV strains (squares), lineages evolved in TSB have the suffix E (circles) and lineages evolved in TSB containing 0.5 MIC gentamicin have the suffix E + G
(triangles). Growth rates were measured in TSB (black symbols) and TSB containing 0.5 MIC gentamicin (white symbols). Several strains evolved in TSB did not grow
with gentamicin at the applied concentration (number provided in parenthesis).
to WT colony phenotype was treated as a stochastic event. The
rate of reversion was estimated to be approximately 10−8–10−9
per cell per generation (Maisnier-Patin et al., 2002), similar to
previous reversion rates of SCV mutants with point mutations
(Lannergård et al., 2008; Pränting and Andersson, 2011). Fitness
in terms of exponential growth rate and stationary CFU of the 12
lineages increased to WT levels (Figures 1 and 2). The relative
growth rates for the compensated strains ranged from 0.89–1.00,
compared to 0.60–0.72 of the ancestral SCVs (Figure 1). The
lineages also gained sensitivity toward gentamicin (Figure 3) and
an assessment of fitness was therefore not possible to do in TSB
supplemented with gentamicin (Figure 1).
None of the 10 lineages derived from deletion SCV mutants
(menD and SAUSA300_1683) and evolved without gentamicin
reverted to WT colony phenotype, even though they displayed
improved fitness in terms of growth rate and CFU in stationary
phase (Figures 1 and 2). The relative growth rates in TSB ofmenD
lineages were 0.65–0.73 compared to 0.63 of the ancestral menD,
while the relative growth rates of SAUSA300_1683 lineages were
0.65–0.76 compared to 0.59 of the ancestral SAUSA300_1683.
Only three of the lineages displayed twofold reduced MIC
compared to respective ancestral SCVs, while the remaining
seven lineages retained the same MIC as respective ancestral
SCVs (Figure 3). The increased growth rates of the 10 lineages
resulted in a trade-off with significantly reduced growth rates for
the majority of the lineages, when grown in TSB supplemented
with gentamicin (Figure 1).
None of the 25 lineages evolved with gentamicin restored
colony phenotype to WT levels. Nonetheless, the majority of
lineages (n = 22/25) displayed improved growth rates in TSB
supplemented with gentamicin, while the growth rates were
increased for 15/25 in TSB (Figure 1). Increased levels of
resistance to gentamicin (2–8 fold) were observed for 20/25
lineages (Figure 3).
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FIGURE 2 | Colony forming unit (CFU) count in stationary phase. CFU count after 24 h growth in TSB of wild type (square), five ancestral SCV strains
(squares), lineages evolved in TSB have the suffix E (circles) and lineages evolved in TSB containing gentamicin have the suffix E + G (triangles).
FIGURE 3 | Gentamicin minimum inhibitory concentration of SCV mutants and evolved lineages. Gentamicin MIC of wild type (square), five ancestral SCV
strains (squares), lineages evolved in TSB have the suffix E (circles) and lineages evolved in TSB containing gentamicin have the suffix E + G (triangles). Numbers
indicate number of lineages with the respective MIC.
Fitness Compensation via Restoration of
Membrane Potential
For the point mutation SCVs evolved in TSB, Sanger-sequencing
of the respective SCV conferring genes (hemH, menA or hemB)
revealed intracodonic mutations in 12/15 lineages (Table 3).
We identified reversion to WT sequence on nucleotide level
in eight lineages and for two lineages on amino acid level.
In two lineages, compensatory mutations substituted the SCV
conferring amino acid with a non-synonymous amino acid
compared to the WT sequence. The acquisition of intracodonic
compensatory mutations in the 12 lineages correlated with
reversion of membrane potential to the level of the WT (Figure 4)
and gentamicin re-sensitization (Figure 3). In the remaining
three lineages, we did not identify any intragenic mutations in
the SCV conferring genes. These lineages indeed displayed lower
levels of fitness amelioration compared to the lineages carrying
intracodonic compensatory mutations. The two lineages (E68
and E69) retained membrane potentials as ancestral SCV and
remained resistant to gentamicin, while lineage E47 displayed
partial growth rate and membrane potential restoration and
gentamicin re-sensitization (Supplementary Table S2).
Inactivation of σB Stress Response
Improves Fitness of SCVs in Absence of
Gentamicin
To identify compensatory mechanisms in the lineages that did
not ameliorate the fitness cost via restoration of the membrane
potential, we WGS all lineages derived from deletion SCV
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TABLE 3 | Spectrum of intragenic compensatory mutations in evolved
lineages derived from SCVs with point mutations.
Compensatory mutation
Strain Lineage SCV mutation Nucleotide Amino acid
MV108 hemH G787T – –
E1 hemH G787T T787G ∗263Glu
E4 hemH G787T T787G ∗263Glu
E21 hemH G787T T787G ∗263Glu
E24 hemH G787T T787G ∗263Glu
E47 hemH G787T – –
MV123 hemB C746T – –
E35 hemB C746T T746C Leu249Pro
E41 hemB C746T T746C Leu249Pro
E50 hemB C746T T746C Leu249Pro
E68 hemB C746T – –
E69 hemB C746T – –
MV127 menA T594A – –
E7 menA T594A A592G Lys198Glu
E15 menA T594A A594T Lys198Asn
E18 menA T594A A593C Lys198Thr
E38 menA T594A A594C Lys198Asn
E44 menA T594A A594C Lys198Asn
mutants (menD and SAUSA300_1683) exhibiting improved
fitness, as well as the five WT control lineages. All of the
evolved SCV lineages still contained the original SCV mutation
(Figure 5; Supplementary Table S3). We identified multiple genes
that acquired mutations in parallel lineages, suggesting selection
for such changes. No mutations from the control lineages were
identified in the evolved SCV lineages, suggesting that mutations
in the SCV lineages were specific to the effect of the SCV
mutations and not due to general adaptation to the growth
environment.
From the menD and SAUSA300_1683 lineages evolved
without gentamicin, 7/10 acquired mutations in genes related to
the σB stress response [spoVG (n = 4), rsbU (n = 1) and rpoF
(n= 2)]. The spoVG gene encodes for the downstream modulator
SpoVG of the σB general stress response (Schulthess et al., 2011),
rsbU encodes for the RsbU activator of σB (Hecker et al., 2007),
while rpoF encodes for the alternative sigma factor SigB (σB)
(Hecker et al., 2007). None of the seven sequenced lineages
evolved with gentamicin had acquired mutations related to the
σB stress response. To determine whether inactivation of the σB
response confers a fitness advantage in TSB we inactivated rpoF
in MV118 with a transposon insertion derived from the Nebraska
Transposon Mutant Library (Fey et al., 2013). The exponential
growth rate of this mutant (MV216) was 7% higher in TSB than
ancestral MV118, however, displayed a significant growth defect
in TSB supplemented with gentamicin (Figure 6). This correlates
well with the observed growth rate trade-off in the majority of
menD and SAUSA300_1683 lineages evolved without gentamicin
(Figure 1). Furthermore, three of the lineages evolved without
gentamicin displayed non-synonymous missense mutations in
the sensor histidine kinase srrB of the staphylococcal respiratory
response two-component system SrrAB (Kinkel et al., 2013). Two
of these lineages did not contain any σB-related mutations.
Independent of whether menD and SAUSA300_1683
lineages evolved with or without gentamicin, 12/17 lineages
acquired mutations in the gene SAUSA300_1252, encoding
a alanine/glycine:cation symporter. Premature stop-codons
and INDELs causing frameshifts suggest that the symporter is
non-essential and that the mutations cause a loss of function. We
inactivated SAUSA300_1252 with a transposon insertion in SCV
FIGURE 4 | Assay for membrane potential of SCV mutants and evolved lineages. The membrane potential was assayed using the fluorescent dye DiOC2(3),
which exhibits green fluorescence in bacterial cells and shifts toward red fluorescence, when the dye molecules self-associate at higher cytosolic concentrations
caused by larger membrane potentials. The red/green ratio of wild type (square), five ancestral SCV strains (squares), lineages evolved in TSB have the suffix E
(circles) and lineages evolved in TSB containing gentamicin have the suffix E + G (triangles).
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FIGURE 5 | Spectrum of compensatory mutations identified in evolved lineages. Mutations in genes identified in evolved lineages derived from deletion SCVs
(menD and SAUSA300_1683) based on whole genome sequencing. The black squares in the matrix denote that the gene contains a mutation. Green squares in the
matrix denote a mutation within 250 bp proximally of the start codon. (−) indicate lineages evolved without gentamicin and (+) indicate lineages evolved with
gentamicin. For detailed information about the mutations, see Supplementary Table S3.
strain MV118 (MV218) to assay the fitness effect in TSB and
TSB supplemented with gentamicin. We could not identify any
difference in terms of exponential growth rate between MV118
and MV218 in TSB or TSB supplemented with gentamicin
(Figure 6).
Evolution in the Presence of Gentamicin
Selects for Additional Resistance
Mutations
Increased levels of gentamicin resistance were detected in
20/25 of the lineages evolved with gentamicin compared to
respective ancestral SCV mutants (Figure 4). We WGS seven
menD and SAUSA300_1683 lineages evolved in the presence of
gentamicin. All of the seven lineages contained mutations in
either fusA and/or SAUSA300_0749, while none of the lineages
evolved without gentamicin contained mutations in these genes
(Figure 5). The gene fusA encodes the elongation factor G (EF-
G) and mutations were identified in three lineages (E72, E75, and
E76). The combination of fusA and a SCV conferring mutations
has previously been described for in vitro selected kanamycin
resistant mutants in S. aureus (Norström et al., 2007; Lannergård
et al., 2011). The gene SAUSA300_0749 encodes a product of
unknown function and has not previously been associated with
gentamicin resistance. A premature stop-codon in strain E74
(Gln3∗) suggests that the gene is non-essential and that loss-of-
function confer the resistance.
DISCUSSION
The impact of antibiotic resistance and compensatory events
on an organism’s fitness are important parameters to consider
when assessing the evolution of antibiotic resistance and the
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FIGURE 6 | σB-mediated fitness cost amelioration and associated
trade-off. The relative growth rates of the SCV strain (MV118) and the
derivatives MV216 (MV118 rpoF::8N6) and MV218 (MV118
SAUSA300_1252::8N6) measured in the absence and presence of
gentamicin (G).
risk of its persistence in bacterial populations (Andersson and
Hughes, 2010, 2011; Hughes and Andersson, 2015). Experimental
evolution has been widely used to assess these two parameters
and the genetic mechanisms involved in reducing the fitness
cost associated with antibiotic resistance. These studies have
mainly been focused on the fitness cost associated with target-site
resistance mechanisms and how this cost can be compensated for
(Björkman et al., 1998, 2000; Paulander et al., 2007, 2010; Brandis
et al., 2012). Therefore, we wanted to investigate how the fitness
cost of the non-target-site aminoglycoside resistance mechanism
conferred by membrane de-polarization, may be compensated for
in the clinically relevant bacterial pathogen S. aureus.
The largest fitness increase was observed in lineages derived
from SCVs with a point mutation (menA, hemB and hemH)
that evolved without gentamicin. In 12/15 lineages, evolved
mutants displayed WT colony morphology and relative fitness
of 0.89–1.00 compared to 0.60–0.72 of the ancestral SCVs
(Figure 1). The fitness compensation correlated with restoration
of membrane potential (Figure 4) and re-sensitization to
gentamicin (Figure 3). Sequencing of the respective resistance
genes revealed intracodonic suppressor mutations in all of the 12
lineages, leading to either nucleotide reversion to WT sequence,
reversion to WT sequence on amino acid level or substitution
of the SCV conferring amino acid mutation (Table 3). For the
remaining three lineages that did not display fully WT phenotype
characteristics, we could not identify any secondary intragenic
mutations. Restored fitness has previously been associated with
reversion in S. aureus SCV isolates with point mutations as the
resistance conferring mutation (Lannergård et al., 2008; Dean
et al., 2014). For target-site resistance mechanisms, compensation
via reversion is rarely selected for (Levin et al., 2000; Paulander
et al., 2007; Andersson and Hughes, 2010; Brandis et al., 2012).
This is a consequence of the higher frequency of compensatory
events (intragenic, extragenic and amplifiaction) restoring fitness
compared to the frequency of reversion mutations and the
bottlenecks associated with serial passage, leading to higher
probability of the loss of reversion mutations due to genetic
drift (Levin et al., 2000). We hypothesize that revertants of SCV
isolates are not lost due to genetic drift in our experimental setup,
as within a single passage revertants constituted approximately
50% of the population and cell density increased 10-fold
(Figure 2). Rather this indicates that revertants can utilize
nutrients that SCVs cannot.
Selection for restoration of membrane potential to WT level
only occurred in lineages derived from point mutation SCVs
that evolved without gentamicin. In the evolved lineages that
originated from SCVs with deletions, restoration of membrane
potential did not occur under any growth conditions. The relative
growth rate increased 2–17% (Figure 1) in these lineages, but
the parental SCV level of gentamicin resistance was maintained
(Figure 3). For 7/10 of lineages derived from SCVs with deletions
evolved without gentamicin, we detected mutations related to
the σB stress response, namely [rpoF (2/10), rsbU (1/10) and
spoVG (4/10) lineages]. Furthermore, we detected mutations in
alanine/glycine transporter encoded by the gene SAUSA300_1252
in 9/10 lineages (Figure 5). The introduction of pre-mature stop-
codons or frame-shift mutations indicated that the mutations
caused a loss-of-function of the gene products. We could show
that transposon inactivation of rpoF in a SCV mutant conferred
improved exponential growth rates in the absence of gentamicin,
but lower growth rates with gentamicin, correlating with the
observation of the passaged lineages containing mutations in σB
stress related genes (Figure 6).
The σB stress response regulates the expression of multiple
non-specific stress mechanisms and virulence factors in S. aureus
(Chan et al., 1998). In a SCV isolate with a hemB mutation it
has been established that the σB stress response is permanently
activated, although the signal transduction behind this activation
remains unknown (Senn et al., 2005; Mitchell et al., 2013).
Decreased levels of ATP, as observed in ETC-deficient SCVs
(Kohler et al., 2003), seem not to be an activator of the σB stress
response in S. aureus (Pané-Farré et al., 2006), as S. aureus lacks
the energy sensor RsbP of Bacillus subtilis (Hecker et al., 2007).
A functional σB stress response, however, is important in the
initial selection of gentamicin resistant SCVs (Mitchell et al.,
2010a,b), but our data indicates that a continuously activated σB
in SCVs impose a fitness cost and is selected against in vitro in the
absence of antibiotic selection. Though we describe a significant
fitness cost associated with the σB stress response in SCVs in vitro,
a functional σB stress response has been reported as an important
mediator in the switching from acute infection to a silent SCV-
phenotype leading to intracellular persistence (Tuchscherr et al.,
2015).
To assess compensatory evolution in the presence of
gentamicin, we selected for mutants with increased fitness at
sub-lethal (1/2 MIC) concentrations of gentamicin. At this
concentration, the exponential growth rates were further
decreased for the ancestral SCVs compared to growth
in antibiotic-free medium, suggesting that membrane-
depolarization does not completely prevent uptake of gentamicin
(Figure 1). The SCV lineages evolved in presence of gentamicin
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(1/2 MIC) experienced enhanced resistance to gentamicin (20/25
lineages) (Figure 3) and increased growth rates in the presence
of gentamicin (22/25 lineages) (Figure 1). Missense mutations
in fusA (3/7 lineages) and/or mutations in SAUSA300_0749 (5/7
lineages) most likely accounted for the increased gentamicin
MIC, as they were identified in multiple parallel lineages and
exclusively in lineages passaged with gentamicin (Figure 5).
Mutations in fusA that encodes for the ribosomal translation
elongation factor, EF-G, can confer resistance to fusidic acid
and aminoglycosides and fusA mutations in SCV strains have
previously been observed (Lannergård et al., 2011). The gene
product of SAUSA300_0749 is a hypothetical protein of unknown
function and has not previously been described in relation to
gentamicin resistance.
Our data show that accumulation of only few de novo
mutations confer high-level resistance to aminoglycosides, which
can be of clinical importance. Selection for increased fitness
in the presence of antibiotics via serial passage has also
been described for target-site resistance mechanisms, such as
rifampicin resistant rpoB mutants (Brandis et al., 2012) and
mupirocin resistant ileS mutants (Paulander et al., 2007). Here
the majority of the compensatory events related to acquisition
of additional intragenic mutations, gene amplifications or
suppressor mutations in related genes (Paulander et al., 2007;
Brandis et al., 2012), e.g., mutations in other ribosomal genes
(rpoA and rpoC) in an rpoB mutant (Brandis et al., 2012). The
data suggests that where target-site mutations may increase the
activity of a target enzyme, while still displaying reduced affinity
of the antibiotic, then further reductions of membrane potential
do not seem feasible for SCVs and therefore non-membrane
potential resistance mechanisms are selected for.
CONCLUSION
Our study highlights three compensatory pathways to ameliorate
the fitness cost associated with SCV gentamicin resistance. The
trajectories of fitness compensation depended on initial mutation
type (point mutation vs. deletion), and whether evolution
proceeded with or without gentamicin. Switching between fast
growing variants and slow growing of S. aureus is associated with
clinically persistent and recurrent infections (Proctor et al., 2006).
Membrane de-polarization and membrane potential restoration
as demonstrated here provides such a switching mechanism.
Whole genome sequencing of clinical SCV isolates in long-term
infections could reveal whether SCVs with mutations in σB stress
response genes is also selected for in the human host or whether
this compensatory event is restricted to laboratory conditions.
Finally, we demonstrate that continued gentamicin selection
pressure can select for additional resistance mutations increasing
gentamicin resistance. Contrarily, gentamicin selection pressure
could potentially be used to trap SCVs in a low fitness state
to limit recurrence of acute infection and then provide a
treatment opportunity with compounds specifically targeting
SCVs (Mitchell et al., 2011).
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